Adalimumab-adaz Injection · 515 days since initial FDA posting
Brand: HYRIMOZ
FDA lists Adalimumab-adaz Injection as To Be Discontinued (Sandoz Inc.).
No availability text on this FDA row.
Adalimumab-adaz Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Adalimumab-adaz Injection
- Manufacturer
- Sandoz Inc.
- Dosage Form
- Injection
- Presentation
- Hyrimoz, Injection, 20 mg/.2 mL (NDC 61314-476-64)
- Package NDC
- 61314-476-64
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Apr 14, 2025
- Last Updated
- Apr 14, 2025
- Therapeutic Category
- Rheumatology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Equivalent Sandoz format is available.
Nearby, Other Adalimumab-adaz Shortage Records
Adalimumab-adaz Injection
Sandoz Inc.
Injection
Adalimumab-adaz Injection
Sandoz Inc.
Injection
Adalimumab-adaz Injection
Sandoz Inc.
Injection
Adalimumab-adaz Injection
Sandoz Inc.
Injection
Adalimumab-adaz Injection
Sandoz Inc.
Injection
Adalimumab-adaz Injection
Sandoz Inc.
Injection
FDA reason on file: Equivalent Sandoz format is available. General shortage guidance lives on the tracker hub.